2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2021
The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts
Clark M, Jembere N, Kupets R. The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts. Preventive Medicine 2021, 150: 106641. PMID: 34048822, DOI: 10.1016/j.ypmed.2021.106641.Peer-Reviewed Original ResearchConceptsSchool-based human papillomavirus (HPV) vaccination programLower genital tract dysplasiaPre-invasive diseaseTreatment of HPVVaccination programGenital wartsCervical dysplasiaCytologic abnormalitiesRelative riskHuman papilloma virus vaccination programmesLow-grade cytologic abnormalitiesHuman papillomavirus vaccination programmeLower genital tractHigh-grade abnormalitiesRelative risk ratiosCervical conizationUnvaccinated womenVaccinated womenHPV vaccineColposcopy servicesUnvaccinated groupVaccinated groupRisk ratioCytology resultsAdministrative databases
2019
Limitations in Correspondence Programs for Cervical Cancer Screening: Who Are the Women We Are Missing?
Clark M, Lee A, Kupets R. Limitations in Correspondence Programs for Cervical Cancer Screening: Who Are the Women We Are Missing? Journal Of Obstetrics And Gynaecology Canada 2019, 41: 1410-1415. PMID: 30803876, DOI: 10.1016/j.jogc.2018.11.034.Peer-Reviewed Original ResearchConceptsPrimary care physiciansCare physiciansHealth care encountersCervical cancerCare encountersMore health care encountersRetrospective observational studyCervical cancer screeningHealth care servicesBasis of ageEligible womenCancer screeningAdministrative databasesObservational studyScreening programCare servicesHealth servicesPhysiciansCorrespondence programWomenFurther riskOutreach methodsCancerMailingInfrequent users
2015
Transvaginal Morcellation
Donat L, Clark M, Tower AM, Menderes G, Parkash V, Silasi DA, Azodi M. Transvaginal Morcellation. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2015, 19: e2014.00255. PMID: 26005318, PMCID: PMC4432719, DOI: 10.4293/jsls.2014.00255.Peer-Reviewed Original ResearchConceptsTransvaginal morcellationLaparoscopic hysterectomyLeiomyomatous uterusUterine morcellationRobot-assisted laparoscopic hysterectomyLaparoscopic-assisted vaginal hysterectomyCharts of womenLarge uterine specimensMean uterine sizeMean blood lossRetrospective case seriesTotal laparoscopic hysterectomyWedge resection techniqueBaseline demographicsPostoperative outcomesSelect patientsSurgical complicationsBlood lossUterine sizeVaginal hysterectomyCase seriesOperative timeInstitution experienceMalignant entitiesMorcellation technique